

February 01, 2024

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Symbol: LALPATHLAB

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Scrip Code: 539524

Sub: Outcome of Board Meeting

Ref: Compliances under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Dear Sir/ Madam,

Please take note that the Board of Directors in their meeting held today i.e. February 01, 2024, inter-alia, considered and approved the following:

- i. Un-Audited Financial Results (Standalone & Consolidated) of the Company for the Quarter & Nine Months ended December 31, 2023.
- ii. Payment of 2nd Interim Dividend of INR 12/- per equity share (@ 120% on a face value of INR 10/- per share) for the FY 2023-24. The record date for the purpose of payment of 2nd Interim Dividend shall be February 13, 2024.

A signed copy of the above Financial Results along with Limited Review Report issued thereon by the Statutory Auditors of the Company under Regulation 33 of the Listing Regulations are attached herewith as **Annexure- I**.

The Board Meeting commenced at 11:30 A.M. and concluded at 01:20 P.M. (IST).

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral

Company Secretary & Compliance Officer

Encl.: As above

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF
INTERIM CONSOLIDATED FINANCIAL RESULTS****To The Board of Directors of Dr. Lal PathLabs Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Dr. Lal PathLabs Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended 31 December, 2023 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the entities listed in Annexure A.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Deloitte
Haskins & Sells LLP**

6. The consolidated unaudited financial results includes the interim financial information/ financial results of three subsidiaries which have not been reviewed by their auditors, whose interim financial information/ financial results reflect total revenues of Rs. 39 million and Rs. 124 million for the quarter and nine months ended 31 December, 2023 respectively, total profit/(loss) after tax of Rs. (4) million and Rs. 1 million for the quarter and nine months ended 31 December, 2023 respectively, total comprehensive loss of Rs. 5 million and Rs. 2 million for the quarter and nine months ended 31 December, 2023 respectively as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information/ financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information/ financial results certified by the Management.

For Deloitte Haskins & Sells LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Jitendra Agarwal
Partner
(Membership No. 87104)
(UDIN: 24087104BKCUBV4762)

Place: Gurugram

Date: 01/02/2024

Annexure A

List of entities consolidated

a) **Parent Company:** Dr. Lal PathLabs Limited


b) **Subsidiaries held directly**

| S. No. | Name of the Entity |
|---------------|--|
| 1 | Paliwal Diagnostics Private Limited |
| 2 | Paliwal Medicare Private Limited |
| 3 | Dr. Lal PathLabs Nepal Private Limited |
| 4 | Dr. Lal PathLabs Bangladesh Private Limited |
| 5 | Dr. Lal Ventures Private Limited |
| 6 | PathLabs Unifiers Private Limited |
| 7 | Dr. Lal PathLabs Kenya Private Limited |
| 8 | Suburban Diagnostics (India) Private Limited |

c) **Subsidiaries held indirectly**

| S. No. | Name of the Entity |
|---------------|-----------------------------------|
| 1 | Centrapath Labs Private Limited |
| 2 | APRL PathLabs Private Limited |
| 3 | Chanre Laboratory Private Limited |

12



Dr. Lal PathLabs Limited
CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085, New Delhi
Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon - 122 001, Haryana
Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended 31 December, 2023

(Rs. in million except as stated)

| Particulars | 3 months ended 31 December, 2023 | Preceding 3 months ended 30 September, 2023 | Corresponding 3 months ended in previous year 31 December, 2022 | Year to date figures for the current period ended 31 December, 2023 | Year to date figures for the previous period ended 31 December, 2022 | Previous year ended 31 March, 2023 |
|--|-------------------------------------|---|--|---|---|---------------------------------------|
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 Income | | | | | | |
| (a) Revenue from operations | 5,389 | 6,013 | 4,894 | 16,812 | 15,259 | 20,169 |
| (b) Other income | 183 | 181 | 105 | 508 | 275 | 417 |
| Total income | 5,572 | 6,194 | 4,999 | 17,320 | 15,534 | 20,586 |
| 2 Expenses | | | | | | |
| (a) Cost of materials consumed | 1,070 | 1,224 | 1,109 | 3,425 | 3,413 | 4,472 |
| (b) Employee benefits expense | 1,090 | 1,054 | 963 | 3,191 | 2,840 | 3,765 |
| (c) Finance costs | 70 | 78 | 91 | 228 | 285 | 375 |
| (d) Depreciation and amortisation expense | 360 | 359 | 379 | 1,070 | 1,126 | 1,502 |
| (e) Fees to collection centers/channel partners | 777 | 852 | 693 | 2,374 | 2,132 | 2,820 |
| (f) Other expenses | 1,046 | 1,105 | 999 | 3,176 | 3,131 | 4,213 |
| Total expenses | 4,413 | 4,672 | 4,234 | 13,464 | 12,927 | 17,147 |
| 3 Profit before tax | 1,159 | 1,522 | 765 | 3,856 | 2,607 | 3,439 |
| 4 Tax expense | | | | | | |
| (a) Current tax | 344 | 431 | 229 | 1,154 | 849 | 1,079 |
| (b) Deferred tax | (7) | (16) | - | (63) | (84) | (51) |
| Total tax expense | 337 | 415 | 229 | 1,091 | 765 | 1,028 |
| 5 Profit for the period (A) | 822 | 1,107 | 536 | 2,765 | 1,842 | 2,411 |
| 6 Other comprehensive income/(loss) | | | | | | |
| Items that will not be reclassified to profit or loss | | | | | | |
| -Remeasurement of the defined benefit obligations | 4 | (2) | 17 | 8 | 50 | 26 |
| -Income tax in relation to the items that will not be reclassified to profit or loss | (1) | 1 | (4) | (2) | (12) | (6) |
| Items that may be reclassified to profit or loss | | | | | | |
| -Exchange differences on translation of foreign operations | (1) | - | (1) | (3) | (2) | (4) |
| Total other comprehensive income/(loss) (B) | 2 | (1) | 12 | 3 | 36 | 16 |
| 7 Total comprehensive income (A+B) | 824 | 1,106 | 548 | 2,768 | 1,878 | 2,427 |
| Profit for the period attributable to: | | | | | | |
| Owners of the Company | 813 | 1,093 | 528 | 2,732 | 1,822 | 2,389 |
| Non-controlling interest | 9 | 14 | 8 | 33 | 20 | 22 |
| | 822 | 1,107 | 536 | 2,765 | 1,842 | 2,411 |
| Other comprehensive income/(loss) for the period attributable to: | | | | | | |
| Owners of the Company | 2 | (1) | 12 | 3 | 36 | 16 |
| Non-controlling interest | - | - | - | - | - | - |
| | 2 | (1) | 12 | 3 | 36 | 16 |
| Total comprehensive income for the period attributable to: | | | | | | |
| Owners of the Company | 815 | 1,092 | 540 | 2,735 | 1,858 | 2,405 |
| Non-controlling interest | 9 | 14 | 8 | 33 | 20 | 22 |
| | 824 | 1,106 | 548 | 2,768 | 1,878 | 2,427 |
| 8 Paid-up equity share capital (Face value of Rs. 10 per share) | 835 | 835 | 834 | 835 | 834 | 834 |
| 9 Other equity | | | | | | 15,829 |
| 10 Earnings per share (Rs.) (Face value of Rs. 10 per share)(not annualised) | | | | | | |
| -Basic | 9.77 | 13.16 | 6.37 | 32.88 | 22.00 | 28.82 |
| -Diluted | 9.76 | 13.12 | 6.35 | 32.81 | 21.92 | 28.74 |

For Identification Only
Deloitte Haskins & Sells LLP

Dr. Lal PathLabs Limited

Notes:

- i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 1 February, 2024. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended December 31, 2023 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group').
- iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iv. During the quarter and nine months ended 31 December 2023, the Parent Company has issued 8,000 and 60,000 equity shares of face value of Rs. 10 each respectively, on exercise of employee stock options.

Further, during the nine months ended 31 December 2023, the Parent Company has issued 49,975 equity shares of face value of Rs. 10 each, to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").
- v. The Board of Directors of the Parent Company have approved second interim dividend of INR 12 per equity share (face value of INR 10 each) at their meeting held on 1 February, 2024.

The Board of Directors of the Parent Company had approved first interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 27 July, 2023 and this was paid on 23 August, 2023.


The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2023. The same was approved by the shareholders in the Annual General Meeting held on 12 September, 2023 and this was paid on 15 September, 2023.
- vi. The Hon'ble New Delhi Bench and Hon'ble Ahmedabad Bench of the National Company Law Tribunal ('Hon'ble Tribunal' or 'NCLT') sanctioned the Scheme of Amalgamation ('Scheme') between the Parent Company (Transferee Company) and its wholly owned subsidiary (Transferor Company) by the name APL Institute of Clinical Laboratory & Research Private Limited (APL) on 13 May, 2022 and 17 March, 2023 respectively.

The appointed date as per the Scheme was 1 April, 2020. The Scheme had envisaged transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company

Pursuant to the Scheme becoming effective, the amalgamation had been accounted for under the 'pooling of interests' method in accordance with Ind AS 103 "Business Combinations" and the assets, liabilities and reserves of the Transferor Company had been accounted for at their book value, in the books of Transferee Company.

Accordingly, the results for the nine months ended 31 December 2022, have been restated to give effect of the amalgamation.
- vii. The Board of Directors of the subsidiaries, Paliwal Medicare Private Limited (PMPL) and Paliwal Diagnostics Private Limited (PDPL) in their meetings held on 25 October, 2021 and 25 October, 2021 respectively had approved the "Scheme of Amalgamation" of PMPL with PDPL w.e.f 1 April, 2021, the appointed date. As per the said scheme, the undertaking of PMPL shall stand transferred to and vested in PDPL on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by National Company Law Tribunal and other statutory approvals.
- viii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- ix. The Indian Parliament has approved the Code on Social Security, 2020 ('the Code') which, inter alia, deals with employee benefits during employment and post-employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified. In view of this, the Group is in the process of assessing the impact of the relevant provisions.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited


(Hon'ble) Brig. Dr. Arvind Lal
Executive Chairman

Place: Gurugram

Date: 1 February, 2024

For Identification Only
Deloitte Haskins & Sells LLP

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

To The Board of Directors of Dr. Lal PathLabs Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Dr. Lal PathLabs Limited** ("the Company"), for the quarter and nine months ended 31 December, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.


For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Jitendra Agarwal
(Partner)
(Membership No. 87104)
(UDIN: 24087104BKCUBU2104)

Place: Gurugram

Date: 01/02/2024



Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon – 122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Standalone Unaudited Financial Results for the quarter and nine months ended 31 December, 2023

(Rs. in million except as stated)

| Particulars | 3 months ended 31 December, 2023 | Preceding 3 months ended 30 September, 2023 | Corresponding 3 months ended in previous year 31 December, 2022 | Year to date figures for the current period ended 31 December, 2023 | Year to date figures for the previous period ended 31 December, 2022 | Previous year ended 31 March, 2023 |
|---|-------------------------------------|--|--|--|---|--|
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 Income | | | | | | |
| (a) Revenue from operations | 4,760 | 5,317 | 4,294 | 14,878 | 13,380 | 17,690 |
| (b) Other income | 151 | 141 | 86 | 442 | 351 | 466 |
| Total income | 4,911 | 5,458 | 4,380 | 15,320 | 13,731 | 18,156 |
| 2 Expenses | | | | | | |
| (a) Cost of materials consumed | 927 | 1,043 | 969 | 2,960 | 2,993 | 3,896 |
| (b) Employee benefits expense | 934 | 901 | 817 | 2,733 | 2,386 | 3,155 |
| (c) Finance costs | 65 | 71 | 83 | 209 | 260 | 344 |
| (d) Depreciation and amortisation expense | 192 | 191 | 208 | 567 | 613 | 821 |
| (e) Fees to collection centers/channel partners | 727 | 808 | 654 | 2,241 | 2,016 | 2,665 |
| (f) Other expenses | 871 | 935 | 807 | 2,655 | 2,535 | 3,367 |
| Total expenses | 3,716 | 3,949 | 3,538 | 11,365 | 10,803 | 14,248 |
| 3 Profit before tax | 1,195 | 1,509 | 842 | 3,955 | 2,928 | 3,908 |
| 4 Tax expense | | | | | | |
| (a) Current tax | 319 | 398 | 218 | 1,076 | 793 | 1,014 |
| (b) Deferred tax | (7) | (19) | (2) | (70) | (76) | (30) |
| Total tax expense | 312 | 379 | 216 | 1,006 | 717 | 984 |
| 5 Profit for the period (A) | 883 | 1,130 | 626 | 2,949 | 2,211 | 2,924 |
| 6 Other comprehensive income/(loss) | | | | | | |
| Items that will not be reclassified to profit or loss | 1 | (5) | 16 | 2 | 47 | 26 |
| -Remeasurement of the defined benefit obligations | | | | | | |
| -Income tax in relation to the items that will not be reclassified to profit or loss | (1) | 1 | (4) | (1) | (12) | (7) |
| Total other comprehensive income/(loss) (B) | - | (4) | 12 | 1 | 35 | 19 |
| 7 Total comprehensive income (A+B) | 883 | 1,126 | 638 | 2,950 | 2,246 | 2,943 |
| 8 Paid-up equity share capital (Face value of Rs. 10 per share) | 835 | 835 | 834 | 835 | 834 | 834 |
| 9 Other equity | | | | | | 16,065 |
| 10 Earnings per share (Rs.) (Face value of Rs. 10 per share) (not annualised) | | | | | | |
| - Basic | 10.78 | 13.60 | 7.55 | 35.50 | 26.66 | 35.28 |
| - Diluted | 10.75 | 13.57 | 7.52 | 35.42 | 26.56 | 35.17 |

For Identification Only
Deloitte Haskins & Sells LLP

Dr. Lal PathLabs Limited

Notes:

- i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 1 February, 2024. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended 31 December, 2023 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iii. During the quarter and nine months ended 31 December 2023, the Company has issued 8,000 and 60,000 equity shares of face value of Rs. 10 each respectively, on exercise of employee stock options.

Further, during the nine months ended 31 December 2023, the Company has issued 49,975 equity shares of face value of Rs. 10 each, to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").
- iv. The Board of Directors of the Company have approved second interim dividend of Rs. 12 per equity share (face value of INR 10 each) at their meeting held on 1 February, 2023.

The Board of Directors of the Company had approved first interim dividend of Rs. 6 per equity share (face value of INR 10 each) at their meeting held on 27 July, 2023 and this was paid on 23 August, 2023.


The Board of Directors of the Company had proposed final dividend of Rs. 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2023. The same was approved by the shareholders in the Annual General Meeting held on 12 September, 2023 and this was paid on 15 September, 2023.
- v. The Hon'ble New Delhi Bench and Hon'ble Ahmedabad Bench of the National Company Law Tribunal ('Hon'ble Tribunal' or 'NCLT') sanctioned the Scheme of Amalgamation ('Scheme') between the Company (Transferee Company) and its wholly owned subsidiary (Transferor Company) by the name APL Institute of Clinical Laboratory & Research Private Limiter (APL) on 13 May, 2022 and 17 March, 2023 respectively.

The appointed date as per the Scheme was 1 April, 2020. The Scheme had envisaged transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company

Pursuant to the Scheme becoming effective, the amalgamation had been accounted for under the 'pooling of interests' method in accordance with Ind AS 103 "Business Combinations" and the assets, liabilities and reserves of the Transferor Company had been accounted for at their book value, in the books of Transferee Company.

Accordingly, the results for the nine months ended 31 December 2022 have been restated to give effect of the amalgamation.
- vi. During the nine months ended 31 December 2023, the Company has made further investment of INR 8 million in its wholly owned subsidiary, Suburban Diagnostics (India) Private Limited (SDIPL) through purchase of ESOPs.
- vii. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- viii. The Indian Parliament has approved the Code on Social Security, 2020 ('the Code') which, inter alia, deals with employee benefits during employment and post-employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified. In view of this, the Company is in the process of assessing the impact of the relevant provisions.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited


(Hon'y) Brig. Dr. Arvind Lal
Executive Chairman

Place: Gurugram
Date: 1 February, 2024

For Identification Only
Deloitte Haskins & Sells LLP